Artivion (NYSE:AORT) Rating Increased to Strong-Buy at Wall Street Zen

Wall Street Zen upgraded shares of Artivion (NYSE:AORT) from a buy rating to a strong-buy rating in a research report released on Sunday.

Other equities research analysts also recently issued reports about the company. Stifel Nicolaus boosted their price target on Artivion from $40.00 to $46.00 and gave the company a “buy” rating in a report on Monday, September 29th. Citigroup reaffirmed an “outperform” rating on shares of Artivion in a report on Friday, October 10th. Weiss Ratings reissued a “sell (d-)” rating on shares of Artivion in a report on Wednesday, October 8th. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $51.00 price target on shares of Artivion in a report on Wednesday. Finally, Needham & Company LLC boosted their price objective on shares of Artivion from $50.00 to $58.00 and gave the company a “buy” rating in a research report on Friday, November 7th. Seven equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $49.11.

Artivion Price Performance

AORT opened at $46.63 on Friday. The company has a debt-to-equity ratio of 0.50, a quick ratio of 2.88 and a current ratio of 3.93. Artivion has a 1-year low of $21.97 and a 1-year high of $48.25. The company has a 50-day moving average of $44.93 and a 200-day moving average of $39.40. The company has a market capitalization of $2.21 billion, a P/E ratio of -194.29 and a beta of 1.60.

Artivion (NYSE:AORT) last posted its quarterly earnings results on Thursday, November 6th. The company reported $0.16 EPS for the quarter, topping analysts’ consensus estimates of $0.14 by $0.02. Artivion had a positive return on equity of 5.98% and a negative net margin of 2.16%.The business had revenue of $113.39 million during the quarter, compared to the consensus estimate of $110.71 million. Artivion’s revenue for the quarter was up 18.9% compared to the same quarter last year. Equities analysts expect that Artivion will post 0.37 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, SVP Jean F. Holloway sold 7,315 shares of Artivion stock in a transaction dated Wednesday, December 3rd. The shares were sold at an average price of $45.30, for a total value of $331,369.50. Following the sale, the senior vice president directly owned 156,093 shares in the company, valued at $7,071,012.90. This trade represents a 4.48% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, SVP Marshall S. Stanton sold 47,376 shares of the company’s stock in a transaction dated Friday, November 21st. The stock was sold at an average price of $45.04, for a total transaction of $2,133,815.04. Following the completion of the transaction, the senior vice president owned 44,753 shares of the company’s stock, valued at approximately $2,015,675.12. This trade represents a 51.42% decrease in their position. The SEC filing for this sale provides additional information. Over the last 90 days, insiders have sold 234,511 shares of company stock worth $10,612,452. 8.10% of the stock is owned by company insiders.

Institutional Trading of Artivion

Large investors have recently added to or reduced their stakes in the business. Aster Capital Management DIFC Ltd boosted its position in Artivion by 402.3% during the 3rd quarter. Aster Capital Management DIFC Ltd now owns 648 shares of the company’s stock worth $27,000 after acquiring an additional 519 shares during the period. Caitong International Asset Management Co. Ltd bought a new stake in shares of Artivion during the third quarter valued at about $27,000. Smartleaf Asset Management LLC lifted its holdings in Artivion by 47.7% in the second quarter. Smartleaf Asset Management LLC now owns 1,667 shares of the company’s stock worth $52,000 after purchasing an additional 538 shares during the period. State of Wyoming bought a new position in Artivion in the 3rd quarter valued at about $80,000. Finally, Quadrant Capital Group LLC bought a new position in Artivion in the 3rd quarter valued at about $92,000. 86.37% of the stock is currently owned by institutional investors and hedge funds.

About Artivion

Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.